ras homolog family member T1 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored RHOT1P3 profile across patient tissues and cancer cell-line models. RHOT1P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RHOT1P3 is differentially expressed in 4, with the highest sampling consensus in READ. Additionally, RHOT1P3 RNA expression shows 9,839 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, READ, and THYM as cancer lineages where RHOT1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOT1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOT1P3 survival associations across molecular data types. RHOT1P3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOT1P3 RNA expression–survival associations across cancer types. High RHOT1P3 expression shows unfavorable associations in UCEC, READ, PCPG, OV and LUSC, but favorable associations in KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for RHOT1P3 RNA expression.
This table summarizes RHOT1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for RHOT1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOT1P3 shows lower tumor expression in READ, ESCA and UCEC and higher tumor expression in PRAD. The READ box plot shows higher RHOT1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.240, t-test p = .026).
This table shows molecular features associated with RHOT1P3 in patient tissues and cancer cell lines. In patient samples, RHOT1P3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
